Cargando…

The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients

BACKGROUND AND AIMS: Extraintestinal manifestations are reported to occur in up to 45% of inflammatory bowel disease (IBD) patients during the course of disease. It is unknown whether colectomy reduces the rate of de novo extraintestinal manifestations (EIMs) or impacts on severity of EIMs following...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roth, René, Vavricka, Stephan, Scharl, Michael, Schreiner, Philipp, Safroneeva, Ekaterina, Greuter, Thomas, Zeitz, Jonas, Misselwitz, Benjamin, Schoepfer, Alain, Barry, Mamadou Pathé, Rogler, Gerhard, Biedermann, Luc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435245/ https://www.ncbi.nlm.nih.gov/pubmed/34431613 http://dx.doi.org/10.1002/ueg2.12125

Ejemplares similares

Extraintestinal Manifestations of Inflammatory Bowel Disease
por: Vavricka, Stephan R., et al.
Publicado: (2015)

Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study
por: Bon, Lorenz, et al.
Publicado: (2019)

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
por: Narula, Neeraj, et al.
Publicado: (2021)

Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study
por: Safroneeva, Ekaterina, et al.
Publicado: (2015)

Factors influencing the outcome of vedolizumab treatment: Real‐life data with objective outcome measurements
por: Mader, Orla, et al.
Publicado: (2021)

Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis
por: Lundberg Båve, Aiva, et al.
Publicado: (2023)

Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes
por: Jansen, Fenna M, et al.
Publicado: (2020)

Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn’s disease patients
por: Greuter, Thomas, et al.
Publicado: (2018)

Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome
por: Ruiz, Pedro A, et al.
Publicado: (2017)

Does colectomy in UC patients impact on the PSC onset?: A national registry brings new insights
por: Liefferinckx, Claire
Publicado: (2023)

Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study
por: Schüle, Solvey, et al.
Publicado: (2017)

Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
por: Hoque, Sami, et al.
Publicado: (2020)

Effect of closed and permanent stoma on disease course, psychological well-being and working capacity in Swiss IBD cohort study patients
por: Bianchi, Rahel, et al.
Publicado: (2022)

Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study
por: Roth, Nina, et al.
Publicado: (2019)

The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort
por: Hiller, Aimee, et al.
Publicado: (2019)

Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6‐week open‐label trial of the EOS‐2 Programme
por: Miehlke, Stephan, et al.
Publicado: (2022)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Is hypertension an extra‐intestinal manifestation of inflammatory bowel disease?
por: Burisch, Johan
Publicado: (2023)

Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study
por: Biedermann, Luc, et al.
Publicado: (2019)

Malignancy rates in Crohn's disease patients with perianal fistula: A German retrospective cohort study
por: Podmore, Bélène, et al.
Publicado: (2023)

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
por: Danese, Silvio, et al.
Publicado: (2019)

Lifestyle factors associated with inflammatory bowel disease: data from the Swiss IBD cohort study
por: Lautenschlager, Severin A., et al.
Publicado: (2023)

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study
por: Grob, Lorenz, et al.
Publicado: (2020)

Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease
por: Kutschera, Maximilian, et al.
Publicado: (2021)

First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses
por: Karner, Max, et al.
Publicado: (2014)

Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort
por: Spalinger, Marianne R., et al.
Publicado: (2016)

Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis
por: Leppkes, Moritz, et al.
Publicado: (2022)

Impact of Overweight and Obesity on Disease Outcome in the Pediatric Swiss Inflammatory Bowel Disease Cohort
por: von Graffenried, Thea, et al.
Publicado: (2022)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
por: Binion, D G, et al.
Publicado: (2008)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis
por: Aherne, Carol M, et al.
Publicado: (2011)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
por: Kruis, W, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_735nl0o45bfo2p7of7djhfpq78